Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 865

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 865
---
 September 30, 2023, the Company issued 627,000 shares of its common stock upon exercise of warrants and received proceeds of $20,000. The exercise price of all shares exercised during the nine months ended September 30, 2023 ranged from $0.001 to $0.14. Common Stock As of September 30, 2024, there were 12,263,203 shares of common stock issued and outstanding. Common stock reserved for future issuance consisted of the following as the period presented:

|                                                                                                                    |     | September 30, 
 2024          |       |
|:-------------------------------------------------------------------------------------------------------------------|:----|:--------------|------:|
|                                                                                                                    |     | -in thousands |       |
| Shares reserved for stock options and restricted stock units to purchase common stock under equity incentive plans |     |               | 2,369 |
| Shares reserved for future issuance of equity awards                                                               |     |               |   702 |
| Shares reserved for exercise of warrants                                                                           |     |               | 2,718 |
| Total                                                                                                              |     |               | 5,789 |

**On April 22, 2024, the Company entered into a settlement agreement and mutual release (the “Settlement Agreement”) by and between the Company and RLB Holdings Connecticut, LLC (“RLB”) to continue RLB’s investment in the Company and to resolve any and all potential claims or causes of action in connection with RLB’s failure to purchase $2.5 million of shares of the Company’s common stock pursuant to a financing agreement, dated as of June 5, 2022, as amended on October 24, 2022, December 5, 2022, March 29, 2023, May 1, 2023, July 21, 2023 and October 13, 2023. Pursuant to the Settlement Agreement, on April 23, 2024, the Company received cash proceeds of $500,000 from RLB and on May 1, 2024, the Company issued 903,995 shares of its common stock to RLB. F-134

During the nine months ended September 30, 2024, the Company issued 786,000 shares of its common stock upon exercise of warrants and received proceeds of $2,000. The exercise price of all shares exercised was $0.001.

During the nine months ended September 30, 2024, the Company issued